The Key Role of NAD+ in Anti-Tumor Immune Response: An Update
Authors:
Open Access
- 15 April 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12
Abstract
Nicotinamide adenine dinucleotide (NAD+) is an important molecule that functions as a co-enzyme in numerous metabolic processes. Generated both through de novo synthesis and via salvage pathways, NAD+ is the substrate for a variety of NAD+-consuming enzymes. Among them is CD38, a cell surface ecto-enzyme widely expressed on different types of cells and endowed with the function of cADP-ribose synthases/NAD+ glycohydrolase. Surface CD38 expression is increased in different hematological and solid tumors, where it cooperates with other ecto-enzymes to produce the immunosuppressive molecule adenosine (ADO). Few studies have explored the correlation of NAD+ levels with T-cell mediated anti-tumor response in preclinical models. We therefore discuss these novel findings, examining the possible contribution of NAD+ depletion, along with ADO production, in the immunosuppressive activities of CD38 in the context of human tumors. Lastly, we discuss the use of pharmacological inhibitors of CD38 and supplementation of different NAD+ precursors to increase NAD+ levels and to boost T cell responses. Such molecules may be employed as adjuvant therapies, in combination with standard treatments, for cancer patients.Keywords
Funding Information
- Fondazione Ricerca Molinette
This publication has 37 references indexed in Scilit:
- The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid TumorsCells, 2019
- CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to TherapyFrontiers in Immunology, 2019
- Canonical and non-canonical adenosinergic pathwaysImmunology Letters, 2019
- Role of CD38 Expression in Diagnosis and Pathogenesis of Chronic Lymphocytic Leukemia and Its Potential as Therapeutic TargetCritical Reviews in Immunology, 2015
- A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytesOncoImmunology, 2013
- NAD+‐metabolizing ecto‐enzymes shape tumor–host interactions: The chronic lymphocytic leukemia modelFEBS Letters, 2011
- Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and PathologyPhysiological Reviews, 2008
- Overexpression of Ecto-5'-Nucleotidase (CD73) promotes T-47D human breast cancer cells invasion and adhesion to extracellular matrixCancer Biology & Therapy, 2007
- NAD+ metabolism in health and diseaseTrends in Biochemical Sciences, 2007
- Ecto‐enzyme and signaling functions of lymphocyte CD 7 3Immunological Reviews, 1998